World's 2nd KRAS Inhibitor Approved For Non-Small Cell Lung Cancer With 80% Efficacy!
NYU Langone Hospitals
Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!
University of Iowa Hospitals and Clinics
Cedars-Sinai Medical Center
Keio University Hospital
